fda sued over tirzepatide Lilly seeks to intervene in compounded lawsuit FDA approval for Zepbound (tirzepatide)

But that decision didnt take effect until 2026, so the outlays on the drugs continued to weigh on the financials throughout 2025

Two of the most anticipated studies this yearlarge-scale, randomized, controlled, and double-blinded trials of the popular obesity and diabetes drug semaglutide for Alzheimers diseasehave unfortunately ended in a dud

[1] Because the cypionate ester markedly increases lipophilicity, the subcutaneous or intramuscular depot undergoes gradual enzymatic hydrolysis, releasing free estradiol that is chemically identical to endogenous estrogen and capable of binding to nuclear estrogen receptors in target tissues

Lojo et al., 2016

doi: 10.1210/en.2014-1314